Pacesetter begins trials of Angeion's Aegis:
This article was originally published in Clinica
Pacesetter has begun clinical trials of Angeion's Aegis implantable cardioverter defibrillator (ICD). The first implant was performed at Ohio State University Medical Center in the US. The cardiac rhythm subsidiary of St Jude Medical is conducting the trials at sites in the US and Europe and will market the product for Angeion following regulatory approval. Minneapolis-based Angeion is continuing trials in the US of its Sentinel 2000 ICD system which already has European approval. Angeion is also developing radio frequency and laser catheter ablation systems.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.